GILD's HIV franchise gains momentum with strong Biktarvy and Descovy demand, Yeztugo growth and a promising pipeline targeting long-term expansion.

By Vincent Mumo Nzilani LONDON/NAIROBI, July 21 (Reuters) - Around 77,000 fewer children worldwide received HIV treatment ...

If approved, ISL/LEN could become the first once-weekly, single-tablet HIV treatment to reach the market as patients rely on ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...

During infection, the human immunodeficiency virus (HIV) inserts itself into the host genome as a chromosomally-integrated provirus that persists in infected cells. Although antiretroviral therapies ...

A mathematical modeling study coordinated by UMC Utrecht has shown that sustained HIV remission (without rebound) or HIV eradication cure scenarios could consistently reduce new HIV infections among ...

UNAIDS chief calls for ‘radical change’ as aid cuts gut HIV clinics and treatment worldwide.

Genetic sequencing of peptides in rebound virus in individuals with HIV who had analytic treatment interruptions (ATIs) confirmed the peptides’ expression in HIV-1 infection, according to data ...

With the help of new scientific and technological developments, the HIV/Aids research community is increasingly turning to an ambitious goal: finding a cure for HIV/Aids. If the world is to get close ...

A Q&A With Shauna Applin, ARNP. AJMC: Despite substantial therapeutic advances since the 1980s, the US is not on pace to achieve the goals of the Ending the HIV Epidemic (EHE) public health initiative ...

As delegates gather in Rio de Janeiro for the International Aids Conference next week, one of the biggest lessons from HIV ...

The Trump administration's cuts to the U.S. Agency for International Development and thousands of global health grants have ...